Healthcare

  • PRA Health Sciences tops Street 2Q forecasts Associated Press - 5 hours ago

    On a per-share basis, the Raleigh, North Carolina-based company said it had net income of 20 cents. Earnings, adjusted for one-time gains and costs, came to 47 cents per share. The results beat Wall Street ...

  • Analysts expect more tie-ups in generic drug business Associated Press - 6 hours ago

    Analysts say they expect more tie-ups are coming in the generic drug industry in the wake of Teva's mammoth deal for the generic drug business of Allergan. The Dutch drugmaker Mylan, which had resisted ...

  • Teva and Restaurant Brands are big market movers Associated Press - 7 hours ago

    Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market: NYSE Teva Pharmaceuticals Industries Ltd., up $10.15 to $72 The generic drugmaker is ...

  • Israel's Teva buys Allergan generic drug company for $40.5B Associated Press - 9 hours ago
    Israel's Teva buys Allergan generic drug company for $40.5B

    Israel's Teva Pharmaceutical Industries Ltd. said Monday it is purchasing Dublin-based Allergan PLC's generic pharmaceuticals business for $40.5 billion, in what Israeli analysts called the largest-ever ...

  • Sanofi paying up to $300M for rare thyroid cancer drug Associated Press - 9 hours ago

    French drugmaker Sanofi said Monday it will pay up to $300 million to buy a thyroid cancer drug from British competitor AstraZeneca. AstraZeneca said it had $48 million in sales of Caprelsa in 2014. The ...

  • Pharma M&A: portfolio theory Financial Times - 9 hours ago

    Friendly M&A is cheaper and simpler than the hostile variety. Luckily for Teva Pharmaceutical it had a choice. On Monday, Teva, a leading generic drugmaker, announced the $40.5bn acquisition of the generics ...

  • Anthem/Cigna/Aetna/Humana: Health risk Financial Times - 12 hours ago

    Anthem has an agreed deal to buy Cigna for $188 a share; Aetna and Humana have shaken hands on $230 for each of the latter's shares. All four health insurers have expressed confidence that the deals will ...

  • Mayor pleads not guilty to medical practice bribery charges Associated Press - 12 hours ago

    A doctor who serves as mayor of a northern New Jersey town pleaded not guilty Monday to charges that he took cash bribes and other kickbacks for referring patients to a medical imaging company. West New ...

  • Biotech high flyers face gravity test Financial Times - 13 hours ago

    Eventually the power of gravity prevails on even the highest flying stocks. Eye-watering valuations for the US biotech sector have dominated Wall Street's bull market run in recent years, with investors ...

  • Magellan Health beats Street 2Q forecasts Associated Press - 16 hours ago

    On a per-share basis, the Scottsdale, Arkansas-based company said it had profit of 17 cents. Earnings, adjusted for one-time gains and costs, came to 56 cents per share. The results exceeded Wall Street ...

  • Allergan sells generic drugs unit to Teva for $40bn Financial Times - 17 hours ago

    Having pulled off the biggest takeover of last year, Allergan, the owner of blockbuster wrinkle treatment Botox, is at it again. This time it is in selling mode, divesting its generic business, which makes ...

  • Teva to buy Allergan generic drug unit for $40.5 bn AFP - Mon, Jul 27, 2015 10:18 AM AEST
    Teva to buy Allergan generic drug unit for $40.5 bn

    Israeli pharmaceutical giant Teva said Monday that it was buying the generic drug business of Allergan for $40.5 billion, consolidating its position as a world leader in generics. Teva will pay $33.75 billion in cash and offer $6.75 billion of its stock to Allergan, the company said, in a major move that will further shake up a drugs industry that has seen a rash of consolidation. Mylan had dismissed Teva's bid in April and on Thursday Mylan's independent foundation said it would exercise a call option allowing it buy shares to control half the company to fend off the hostile takeover.

  • Allergan to acquire Naurex as Teva talks continue Associated Press - Mon, Jul 27, 2015 5:19 AM AEST

    Allergan PLC, the Dublin-based pharmaceutical giant, announced Sunday it has agreed to buy Naurex, a developer of drugs for depression and other central nervous system disorders, for $560 million. Naurex, ...

  • Bioven seeks IPO to help market Cuban cancer drug Financial Times - Sun, Jul 26, 2015 11:25 PM AEST

    A Malaysian biotech company developing a cancer drug discovered in Cuba is planning to float in London. Bioven has its origins in Malaysia's friendly relations with Cuba during the latter's long isolation ...

  • Teva closes in on Allergan's generics unit Financial Times - Sun, Jul 26, 2015 9:05 AM AEST

    Teva Pharmaceutical, the Israeli drugmaker, is nearing a deal to acquire Allergan's generics drug unit for between $40bn and $45bn, according to people familiar with the matter. A deal, which one person ...

  • Do 3 big insurers flash red for govt? Mergers get close look Associated Press - Sat, Jul 25, 2015 10:17 AM AEST

    Would a reduction from five health insurance giants to three trigger a flashing light for regulators concerned about industry competition? That's how many big companies could remain after the proposed ...

  • FDA OKs breakthrough cholesterol drug for high-risk patients Associated Press - Sat, Jul 25, 2015 8:31 AM AEST
    FDA OKs breakthrough cholesterol drug for high-risk patients

    The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades. The drug from Sanofi and ...

  • Bristol-Myers wins approval for 1st hepatitis C type 3 drug Associated Press - Sat, Jul 25, 2015 7:57 AM AEST

    An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options — all much more effective but extremely ...

  • Battle coming for blockbuster cholesterol drugs CNBC - Sat, Jul 25, 2015 5:59 AM AEST
    Battle coming for blockbuster cholesterol drugs

    One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually, straining insurance plans.

  • Why the 2010 health care law led to insurance merger mania Associated Press - Sat, Jul 25, 2015 5:40 AM AEST

    The health care overhaul law has reshaped the health insurance business, and one consequence is more than $100 billion in mergers and acquisitions over the last few years. Anthem Inc.'s purchase of Cigna ...

  • FDA OK's Odomza from Novartis for common skin cancer type Associated Press - Sat, Jul 25, 2015 4:49 AM AEST

    A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval. Odomza (pronounced ah-DOMM'-zoh) was approved for patients ...

  • Mega-health deals bloom in July, Anthem bids $48B for Cigna Associated Press - Sat, Jul 25, 2015 3:58 AM AEST
    Mega-health deals bloom in July, Anthem bids $48B for Cigna

    Anthem is buying rival Cigna for $48 billion in a deal that would create the nation's largest health insurer by enrollment, covering about 53 million U.S patients. In just three weeks, starting with Aetna's ...

  • Glance: The new 'Big Three' of health coverage Associated Press - Sat, Jul 25, 2015 3:34 AM AEST

    Anthem Inc.'s $48 billion purchase of rival Cigna Corp. is set to create the nation's largest health insurance company. The combination, in tandem with Aetna Inc.'s pending purchase of rival insurer Humana ...

  • US stocks edge mostly lower; Amazon soars on surprise profit Associated Press - Sat, Jul 25, 2015 12:18 AM AEST
    US stocks edge mostly lower; Amazon soars on surprise profit

    U.S. stocks drifted mostly lower in early trading Friday as investors reviewed the latest batch of corporate earnings and deal news. Health care stocks were among the biggest decliners. KEEPING SCORE: ...

  • Anthem acquiring rival Cigna in $54.2 billion deal Associated Press - Fri, Jul 24, 2015 8:20 PM AEST

    Anthem is buying rival Cigna in a deal valued at $54.2 billion that will create the nation's largest health insurer by enrollment, covering about 53 million patients in the U.S. The deal comes just three ...

  • Anthem to buy Cigna for $54.2 billion, creating insurance giant with 53 million US patients Associated Press - Fri, Jul 24, 2015 8:06 PM AEST

    Anthem to buy Cigna for $54.2 billion, creating insurance giant with 53 million US patients.

  • Sunesis tumbles as FDA says it won't approve cancer drug Associated Press - Fri, Jul 24, 2015 7:37 AM AEST

    Shares of Sunesis Pharmaceuticals plunged in aftermarket trading Thursday after the company said it will focus on trying to get its blood cancer drug Qinprezo on the market in Europe because regulators ...

  • Mylan puts up barrier to Teva with Dutch legal maneuver Associated Press - Fri, Jul 24, 2015 3:31 AM AEST

    Drugmaker Mylan on Thursday used a provision of Dutch law to put up a barrier that makes it harder for larger rival Teva Pharmaceutical Industries to buy the company. Dutch companies like Mylan can create ...

  • Eli Lilly CEO: Obamacare out-of-pocket costs high CNBC - Fri, Jul 24, 2015 12:40 AM AEST
    Eli Lilly CEO: Obamacare out-of-pocket costs high

    Eli Lilly chief John Lechleiter tells CNBC all aspects of health care need to be addressed, including the high costs of Obamacare for many Americans.

  • Utah Medical posts 2Q profit Associated Press - Thu, Jul 23, 2015 11:37 PM AEST

    On a per-share basis, the Midvale, Utah-based company said it had profit of 77 cents. The medical device maker posted revenue of $10.4 million in the period. Utah Medical shares have declined nearly 3 ...

  • Eli Lilly tops Street 2Q forecasts, raises outlook Associated Press - Thu, Jul 23, 2015 9:38 PM AEST

    Eli Lilly and Co. on Thursday reported better-than-expected second-quarter profit on a boost from its recently acquired animal health unit and raised its outlook. The company reported second-quarter earnings ...

  • Anthem closes in on $48bn Cigna takeover Financial Times - Thu, Jul 23, 2015 9:44 AM AEST

    Anthem is close to acquiring Cigna for more than $48bn, in what would be the second health-insurance deal to be spurred as a direct reaction to Obamacare. Anthem would value Cigna at $187 per share, said ...

  • Investors join push for more transparency on drug trials Financial Times - Thu, Jul 23, 2015 9:00 AM AEST

    Dozens of big investors have backed a campaign by British activists for more transparency in the pharmaceuticals industry. BNP Paribas and Aviva Investors are among 85 pension funds and asset managers ...

  • Eli Lilly: Experimental Alzheimer's drug shows some benefit Associated Press - Thu, Jul 23, 2015 7:16 AM AEST
    Eli Lilly: Experimental Alzheimer's drug shows some benefit

    Eli Lilly & Co. reported Wednesday that an experimental medication might slow mild Alzheimer's if people take it early enough, one of a handful of drugs in late-stage testing in the frustrating hunt for ...

  • AstraZeneca suffers setback after drug fails to treat eye cancer Financial Times - Thu, Jul 23, 2015 4:02 AM AEST

    AstraZeneca revealed on Wednesday that it has suffered a setback in its crucial cancer drugs pipeline with the failure of an experimental treatment for a rare form of melanoma. Analysts described it as ...